Saltar al contenido
Merck

1271700

USP

Fluconazole

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

Fluconazole, 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C13H12F2N6O
Número de CAS:
Peso molecular:
306.27
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fluconazole

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1

InChI

1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

InChI key

RFHAOTPXVQNOHP-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application


  • Enhanced antifungal activity of fluconazole: A study optimized fluconazole-embedded transfersomal gel, demonstrating improved antifungal activity and compatibility. This research is crucial for enhancing fluconazole′s efficacy against resistant fungal strains, making it a pivotal tool in the fight against fungal infections (Cheng et al., 2024).

  • Antifungal mechanisms against drug-resistant strains: Research on the antifungal activity of a trypsin inhibitor from chia seeds against fluconazole-resistant Candida species assessed its potential as a novel therapeutic approach. This study contributes valuable insights into natural compounds enhancing fluconazole′s effectiveness, crucial for developing alternative antifungal therapies (Nogueira et al., 2024).

  • Advancements in fungal pathogenesis: The isolation and identification of Wickerhamiella tropicalis from blood culture using MALDI-MS highlight innovative diagnostic techniques that enhance the understanding of fungal pathogenesis. This research is essential for advancing microbial diagnostics and tailoring treatments to combat invasive fungal infections effectively (Takei et al., 2024).

Biochem/physiol Actions

Fluconazole is an antifungal agent. It is highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethyllation. Fluconazole is a potent inhibitor of CYP2C9. Fluconazole interferes with fungal ergosterol synthesis and downregulates the metallothionein gene.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3 - Lact. - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Fluconazole in Dextrose Injection
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 1907-1907 (2018)
Fluconazole
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(6), 1901-1901 (2020)
Fluconazole in Sodium Chloride Injection
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 1909-1909 (2018)
Wei Zhao et al.
Clinical pharmacokinetics, 53(11), 1005-1018 (2014-08-27)
Selection of the first-dose-in-neonates is challenging. The objective of this proof-of-concept study was to evaluate a pharmacokinetic bridging approach to predict a neonatal dosing regimen. We selected fluconazole as a paradigm compound. We used data from studies in juvenile mice
Kim C M van der Elst et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 59(11), 1527-1533 (2014-08-26)
Fluconazole is recommended as first-line treatment in invasive candidiasis in children and infants. Although timely achievement of adequate exposure of fluconazole improves outcome, therapeutic drug monitoring is currently not recommended. We conducted a retrospective study of critically ill children treated

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico